This document discusses strategies for developing new anti-influenza drugs, as resistant strains have emerged. It describes targeting host factors required for viral replication as an alternative approach. A screening identified hundreds of host factors influencing viral replication, but validating drug targets in these remains challenging. The document then provides details on influenza A virus entry, replication, assembly and release. It notes that while much is known, many details remain unclear, and identifying compounds targeting any stage of the viral lifecycle could provide insights and new therapies.